Introduced
by
To exclude from the gross receipts basis of the Michigan Business Tax receipts that are received by health care providers from the administration of antineoplastic drugs and other cancer chemotherapy, biological monitoring, therapeutic agents, and other supportive drugs given to cancer or blood disorder patients.
Referred to the Committee on Tax Policy
Reported without amendment
Without amendment and with the recommendation that the bill pass.
Passed in the House 102 to 2 (details)
To exclude from the gross receipts basis of the Michigan Business Tax receipts that are received by health care providers from the administration of antineoplastic drugs and other cancer chemotherapy, biological monitoring, therapeutic agents, and other supportive drugs given to cancer or blood disorder patients.
Referred to the Committee on Finance
